The DanGer shock trial substudy compared microaxial flow pump (mAFP) and standard care in improving cardiac output and lowering pulmonary pressures in patients with STEMI-related cardiogenic shock. The results were reported in the Journal of the American College of Cardiology.

A substudy of the Danish-German (DanGer) shock trial investigated the effect of the microaxial flow pump (mAFP) on hemodynamic parameters, including cardiac output (CO), cardiac power output (CPO), and pulmonary artery pressure (PAP).

Of 324 patients admitted to the cardiac intensive care unit, 223 underwent pulmonary artery catheter monitoring. Of these, 125 received mAFP therapy while 98 received standard care. The study reported that patients treated with mAFP consistently have higher CO after 12 hours, lower mean PAP, and lower pulmonary capillary wedge pressure (PCWP) than patients on standard care. Median CPO values were also significantly higher in the mAFP group (0.68 W vs 0.56 W).